Cyteph Completes Enrollment for First-in-Human CYT-101 Trial in Recurrent Glioblastoma
核心洞察
Cyteph (搜索) has successfully completed recruitment for its Phase I clinical trial of CYT-101, a novel off-the-shelf CMV-specific T cell therapy targeting recurrent glioblastoma multiforme (搜索).
The therapy uniquely targets CMV antigens (搜索) present on tumor cells but absent in surrounding healthy tissue, enabling a highly targeted treatment approach for this aggressive brain cancer (搜索).
Key safety and efficacy readouts from the dose-escalation study are expected at the end of Q4 2025, with results informing future clinical development.
Cyteph (搜索) Pty Ltd has successfully completed patient recruitment for its first-in-human Phase I clinical trial of CYT-101, marking a significant milestone in the development of a novel immunotherapy for recurrent glioblastoma multiforme (搜索) (GBM (搜索)). The Australian biotechnology company announced the completion on October 7, 2025, highlighting strong demand from clinical collaborators and patients for innovative treatment options.
Novel CMV-Targeted Approach
CYT-101 represents a novel off-the-shelf, HLA-matched CMV-specific T cell therapy designed for the treatment of glioblastoma multiforme (搜索) and other solid cancers (搜索). The therapy's unique advantage lies in its targeting of CMV antigens (搜索), which are detected on tumor cells while remaining absent in surrounding healthy tissue. This characteristic enables a highly targeted therapeutic approach that could potentially minimize damage to normal brain tissue.
"The unique advantage of targeting CMV antigens (搜索) on GBM (搜索) cells is that they are detected on tumour cells while not found in surrounding healthy tissue," according to the company's announcement. By harnessing allogeneic CMV-specific T cell therapy, CYT-101 has the potential to offer improved outcomes for GBM patients who currently face limited treatment options.
Clinical Trial Design and Timeline
The Phase I study is being conducted in collaboration with Briz Brain & Spine (搜索) and Newro Foundation (搜索), evaluating the safety, tolerability, and preliminary signals of efficacy of CYT-101 in patients with recurrent GBM (搜索). The trial follows participants through dose-escalation cohorts, with key readouts expected at the end of Q4 2025.
Professor Rajiv Khanna, Chief Scientific Officer and Founder of Cyteph (搜索), expressed satisfaction with the enrollment completion, stating, "We are pleased to have completed enrolment, reflecting the strong demand from clinical collaborators and patients for innovative treatment options for GBM (搜索). This milestone marks an important step forward in our mission to bring transformative therapies to patients with few existing options."
Addressing Critical Unmet Need
Glioblastoma multiforme (搜索) represents one of the most challenging cancers to treat, described as an aggressive brain cancer (搜索) and one of the deadliest solid cancers (搜索) in adults. The limited treatment options available for GBM (搜索) patients underscore the critical need for innovative therapeutic approaches like CYT-101.
Professor David Walker, neurosurgeon and spinal surgeon at Briz Brain & Spine (搜索) and lead clinical investigator for the CYT-101 clinical trial, emphasized the significance of the milestone: "Completing recruitment is a critical milestone for any clinical program, and it underscores the dedication of our team, and the patients who make this research possible."
Development Path Forward
Results from this Phase I study will inform the design of subsequent clinical trials and support the continued development of CYT-101 as a novel treatment approach for glioblastoma and other high-unmet-need solid cancers (搜索). The trial is funded through Australia's national biotech incubator CUREator (搜索), supporting the advancement of this promising immunotherapy.
Cyteph (搜索) operates as a spin-out biotechnology company from QIMR Berghofer (搜索), a leading medical research institute based in Brisbane, Australia, positioning the company within a strong research ecosystem for continued development of innovative cancer therapies.